PMID- 29468275
OWN - NLM
STAT- MEDLINE
DCOM- 20190610
LR  - 20190613
IS  - 1433-0458 (Electronic)
IS  - 0017-6192 (Linking)
VI  - 66
IP  - 4
DP  - 2018 Apr
TI  - [The innate immune system in oropharyngeal squamous cell carcinoma : Immune 
      modulation by HPV].
PG  - 301-307
LID - 10.1007/s00106-018-0480-y [doi]
AB  - Based on clinical and experimental data, oropharyngeal squamous cell carcinomas 
      (OPSCC) associated with human papillomavirus (HPV) have been recognized as 
      a distinct entity of head and neck cancers. However, outside of clinical trials, 
      HPV status currently has no impact on treatment. The natural replication cycle of 
      HPV takes place in epithelial cells, and is thus spatially separated from 
      cytotoxic immune cells in the epidermis. Dendritic cells (Langerhans cells, LC), 
      however, are frequent in this upper dermal layer. The ability of LC to process 
      antigens, migrate, and, ultimately activate T cells is inhibited by the activity 
      of the viral oncoproteins (E5-E7). Downregulation of functional human leukocyte 
      antigen I (HLA-I) epithelial cell surface expression contributes to LC 
      inhibition. However, due to their absence in upper skin layers, corresponding 
      activation of natural killer (NK) cells via missing-self recognition is not 
      relevant. Genome-wide analyses have revealed specific expression signatures for 
      HPV-associated OPSCC that are distinct from HPV-negative cancers. Interestingly, 
      aberrations in HLA-I genes were common in HPV-associated OPSCC. Our own findings 
      indicate more frequent infiltration of HPV-associated OPSCC by CD56-positive 
      (CD56(+)) NK cells, which might be related to HLA-I downregulation during 
      HPV-associated carcinogenesis. In patients with OPSCC, CD56 positivity correlates 
      with improved prognosis after conventional therapy. This could be evidence for 
      HPV-associated OPSCC being especially eligible for novel immune-based therapies 
      and an indication that immunological data should be included in the design of 
      clinical trials.
FAU - Wagner, S
AU  - Wagner S
AD  - Klinik fur HNO-Heilkunde, Kopf‑, Halschirurgie, Universitatsklinikum Giessen, 
      Justus-Liebig-Universitat Giessen, Giessen, Deutschland. 
      steffen.wagner@hno.med.uni-giessen.de.
AD  - Kopf-Hals-Tumorforschung, Klinik fur HNO-Heilkunde, Kopf‑/Halschirurgie, 
      Justus-Liebig-Universitat Giessen, Aulweg 128 (ForMED), 35392, Giessen, 
      Deutschland. steffen.wagner@hno.med.uni-giessen.de.
FAU - Bockmann, H
AU  - Bockmann H
AD  - Klinik fur HNO-Heilkunde, Kopf‑, Halschirurgie, Universitatsklinikum Giessen, 
      Justus-Liebig-Universitat Giessen, Giessen, Deutschland.
AD  - Kopf-Hals-Tumorforschung, Klinik fur HNO-Heilkunde, Kopf‑/Halschirurgie, 
      Justus-Liebig-Universitat Giessen, Aulweg 128 (ForMED), 35392, Giessen, 
      Deutschland.
FAU - Gattenlohner, S
AU  - Gattenlohner S
AD  - Institut fur Pathologie, Universitatsklinikum Giessen, Justus-Liebig-Universitat, 
      Giessen, Deutschland.
FAU - Klussmann, J P
AU  - Klussmann JP
AD  - Klinik fur HNO-Heilkunde, Kopf‑, Halschirurgie, Universitatsklinikum Giessen, 
      Justus-Liebig-Universitat Giessen, Giessen, Deutschland.
AD  - Kopf-Hals-Tumorforschung, Klinik fur HNO-Heilkunde, Kopf‑/Halschirurgie, 
      Justus-Liebig-Universitat Giessen, Aulweg 128 (ForMED), 35392, Giessen, 
      Deutschland.
FAU - Wittekindt, C
AU  - Wittekindt C
AD  - Klinik fur HNO-Heilkunde, Kopf‑, Halschirurgie, Universitatsklinikum Giessen, 
      Justus-Liebig-Universitat Giessen, Giessen, Deutschland.
AD  - Kopf-Hals-Tumorforschung, Klinik fur HNO-Heilkunde, Kopf‑/Halschirurgie, 
      Justus-Liebig-Universitat Giessen, Aulweg 128 (ForMED), 35392, Giessen, 
      Deutschland.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Das angeborene Immunsystem beim Oropharynxkarzinom : Immunmodulation durch HPV.
PL  - Germany
TA  - HNO
JT  - HNO
JID - 2985099R
SB  - IM
MH  - *Carcinoma, Squamous Cell/immunology/virology
MH  - Genome-Wide Association Study
MH  - Humans
MH  - *Oropharyngeal Neoplasms/immunology/virology
MH  - *Papillomaviridae
MH  - *Papillomavirus Infections/immunology
OTO - NOTNLM
OT  - Natural killer cells
OT  - Oropharyngeal cancer
OT  - Papillomavirus infections
OT  - Prognosis
OT  - Tumor escape
EDAT- 2018/02/23 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/02/23 06:00
PHST- 2018/02/23 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2018/02/23 06:00 [entrez]
AID - 10.1007/s00106-018-0480-y [pii]
AID - 10.1007/s00106-018-0480-y [doi]
PST - ppublish
SO  - HNO. 2018 Apr;66(4):301-307. doi: 10.1007/s00106-018-0480-y.